A rapid scoping review of the feasibility of a COX-2 inhibition strategy for patients with transitional cell bladder cancer. A report to the funders

Centre for Reviews and Dissemination (CRD)
Record ID 32004000691
English
Authors' objectives:

A rapid scoping review of the feasibility of a COX-2 inhibition strategy for patients with transitional cell bladder cancer was undertaken. The review was to support the Bladder COX-2 Inhibition Trial (BOXIT) proposal by the NCRI Bladder Cancer Clinical Study Group. The review mapped, but did not evaluate, the evidence base of the published literature on the effectiveness and cost-effectiveness of COX-2 inhibitors for transitional bladder cancer.

Authors' recommendations: The literature search identified 129 records, four of which met the inclusion criteria. There were two published studies and two ongoing studies. The published studies comprised one non-randomised controlled trial and one case report (both published over 15 years ago), and the ongoing studies comprised two randomised controlled trials (RCTs). The results of this scoping exercise indicate that few studies exist for COX-2 inhibitors used for bladder cancer. There is no strong evidence base of existing published research in the area. Two RCTs of COX-2 inhibitors (alone or combined with other treatment) for bladder cancer, are ongoing.
Details
Project Status: Completed
URL for project: http://www.york.ac.uk/inst/crd/projects/cox-2_inhibitors_bladder_cancer.htm
Year Published: 2004
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England
MeSH Terms
  • Cyclooxygenase Inhibitors
  • Urinary Bladder Neoplasms
Contact
Organisation Name: University of York
Contact Address: University of York, York, Y01 5DD, United Kingdom. Tel: +44 1904 321040, Fax: +44 1904 321041,
Contact Name: crd@york.ac.uk
Contact Email: crd@york.ac.uk
Copyright: Centre for Reviews and Dissemination (CRD)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.